Development of a Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple Myeloma PatientsJeremy M. Kinder, Terry J. Fry, Neal Van Hoeven et al.|Blood|2023Cited by 3
Preclinical Efficacy of a Novel CD8-Targeted Fusosome for In Vivo CAR T Cell TherapyVandana Chaturvedi, Terry J. Fry, Jesse Green et al.|Blood|2023Cited by 3
BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor ModelsJeremy M. Kinder, Aaron E. Foster, Chanel Athena-Estrada et al.|Blood|2022Cited by 1
Abstract 2734: Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomesBrian Dolinski, Terry J. Fry, Vandana Chaturvedi et al.|Cancer Research|2023Cited by 0
Abstract 2735: Development of a novel, fully human anti-CD19 chimeric antigen receptor for <i>in vivo</i> delivery via CD8-targeted fusosomeJeremy M. Kinder, Aaron E. Foster, Christie Ciarlo et al.|Cancer Research|2023Cited by 0